Vision Loss News and Research

RSS

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

Regeneron receives FDA approval for Eylea to treat wet AMD

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

18 Nov 2011

Lower glycemic index diet may delay onset of AMD-like lesions

Feeding older mice a lower glycemic index (GI) diet consisting of slowly-digested carbohydrates delays the onset of age-related, sight-threatening retinal lesions, according to a new study from the Laboratory for Nutrition and Vision Research at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University.

14 Nov 2011

GHSU expert to again coordinate two national diabetes initiatives

Two national efforts supporting diabetes research will again be coordinated by a Georgia Health Sciences University bioinformatics expert.

10 Nov 2011

National lupus organizations urge NICE to recommend Benlysta for coverage

National lupus organizations in more than 28 countries, and individuals with lupus and their families around the world, are rallying to protect access to new treatments and the development of future therapies to treat lupus.

1 Nov 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Zeaxanthin reduces risk for AMD

St. Louis-based ZeaVision, LLC announced that three recent groundbreaking studies demonstrate that Zeaxanthin (zee-uh-zan-thin), the predominate protective pigment in the back of the eye, reduces the risk for Age-Related Macular Degeneration (AMD) and benefits the treatment of advanced AMD, a condition that destroys central vision and affects millions of Americans.

24 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration has approved its Investigational New Drug application for the Phase I/IIa clinical development of UshStat, a novel gene-based treatment for Usher syndrome type 1B.

18 Oct 2011

NIH grants support SUNY's neuroscience, pediatric pharmacology and vision research

The State University of New York has received two grants totaling more than $4.3 million from the National Institutes of Health (NIH) to support neuroscience and pediatric pharmacology and vision research as part of SUNY REACH, a collaborative research network of SUNY's four academic health centers and the College of Optometry.

15 Oct 2011

Logistic regression models identify risk factors for open angle glaucoma

Early detection and diagnosis of open angle glaucoma important so that treatment can be used in the early stages of the disease developing to prevent or avoid further vision loss.

7 Oct 2011

Cocaine use linked to increased risk of open-angle glaucoma

A study of the 5.3 million men and women seen in Department of Veterans Affairs outpatient clinics in a one-year period found that use of cocaine is predictive of open-angle glaucoma, the most common type of glaucoma.

30 Sep 2011

Two computerized tests increase ability to detect remaining vision in patients with RP

Two new computerized tests increase the ability to measure remaining vision in patients with retinitis pigmentosa (RP) and other blinding diseases, reports a study in the October issue of Optometry Vision Science, official journal of the American Academy of Optometry.

27 Sep 2011

Embryonic stem cell therapy for incurable Stargardt eye disease

...

26 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Lucentis receives Health Canada approval to treat vision loss from DME

Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.

14 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

Insight into molecular basis of Enhanced S-Cone Syndrome

A new research report published in The FASEB Journal will help ophthalmologists and scientists better understand a rare genetic disease that causes increased susceptibility to blue light, night blindness, and decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome.

2 Sep 2011